United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis, b. ovatus, b. thetaiotaomicron, or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin/tazobactam-susceptible acinetobacter baumannii , haemophilus influenzae , klebsiella pneumoniae , and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2)] . piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplica

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 4.0 g/vial; tazobactam as sodium salt 0.5 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 4.0 g/vial; tazobactam as sodium salt 0.5 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 4.0 g/vial; tazobactam as sodium salt 0.5 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 2.0 g/vial; tazobactam as sodium salt 0.25 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 2.0 g/vial; tazobactam as sodium salt 0.25 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - piperacillin as sodium salt; tazobactam as sodium salt - powder for solution for infusion - piperacillin as sodium salt 2.0 g/vial; tazobactam as sodium salt 0.25 g/vial - tazobactam - - treatment of systemic and/or local infections caused by susceptible organisms.- piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years. - appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

United States - English - NLM (National Library of Medicine)

wyeth piperacillin division of wyeth holdings corporation, a subsidiary of pfizer - tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w), piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx) - tazobactam 4.5 g in 180 ml - zosyn (piperacillin and tazobactam for injection, usp) is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, β-lactamase producing strains of the designated microorganisms in the specified conditions listed below: appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin-resistant, β‑lactamase producing strains of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . the individual members of this group were studied in less than 10 cases. uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections caused by piperacillin-resistant, β‑lactamase producing strains of staphylococcus aureus . postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, β‑lactamase producing strains of escher

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tazobactam sodium, quantity: 536.6 mg (equivalent: tazobactam, qty mg); piperacillin sodium, quantity: 4.17 g (equivalent: piperacillin, qty g) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - piperacillin sodium, quantity: 2.085 g (equivalent: piperacillin, qty g); tazobactam sodium, quantity: 268.3 mg (equivalent: tazobactam, qty mg) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.